Novel antipsychotics in bipolar and schizoaffective mania

CJ Slooff*

*Corresponding author for this work

    Research output: Contribution to journalReview articlepeer-review

    24 Citations (Scopus)

    Abstract

    Objective: Novel antipsychotics are increasingly used in the treatment of bipolar and schizoaffective mania. This paper presents an overview of the controlled studies in this field.

    Method: Using cross-references, a computerized search was performed on MEDLINE and EMBASE psychiatry covering the period 1990-2002.

    Results: Olanzapine and risperidone, added to mood stabilizers, and olanzapine as monotherapy enjoy the most evidential support in terms of efficacy and side-effect profile for their use in acute bipolar mania. The use of modern antipsychotics in bipolar prophylaxis and in both the short- and long-term treatment of schizomania has not been widely studied yet.

    Conclusion: More controlled trials are still needed comparing modern antipsychotics as monotherapy and adjunctive to mood stabilizers with conventional antipsychotics, lithium, anticonvulsants and with each other in short-term and, especially, maintenance treatment of (schizo)mania. Partly based on controlled studies, olanzapine, risperidone and other modern antipsychotics could become preferable for these indications.

    Original languageEnglish
    Pages (from-to)405-419
    Number of pages15
    JournalActa Psychiatrica Scandinavica
    Volume109
    Issue number6
    Publication statusPublished - Jun-2004

    Keywords

    • antipsychotic agents
    • psychotic disorders
    • bipolar disorder
    • clozapine
    • risperidone
    • olanzapine
    • quetiapine
    • ziprasidone
    • aripiprazole
    • PSYCHOTIC MOOD DISORDERS
    • RANDOMIZED CONTROLLED-TRIAL
    • PLACEBO-CONTROLLED TRIAL
    • 6-MONTH FOLLOW-UP
    • DOUBLE-BLIND
    • RISPERIDONE TREATMENT
    • CLINICAL PREDICTORS
    • DYSPHORIC MANIA
    • PHARMACOLOGICAL TREATMENT
    • ATYPICAL ANTIPSYCHOTICS

    Cite this